BMJ Open (Aug 2023)

Evaluation of the efficacy and safety of an integrated telerehabilitation platform for home-based cardiac REHABilitation in patients with heart failure (E-REHAB): protocol for a randomised controlled trial

  • Ryosuke Murai,
  • Keisuke Kida,
  • Hiroshi Suzuki,
  • Yasushi Sakata,
  • Takayuki Ise,
  • Shin-ichiro Miura,
  • HIROKAZU KONDO,
  • Yuichi Tamura,
  • Misato Chimura,
  • Tatsunori Taniguchi,
  • Kensuke Takabayashi,
  • Shinji Koba,
  • Hiroyuki Miura,
  • Emi Maekawa,
  • Koki Matsuo,
  • Wataru Fujimoto,
  • Shunsuke Imai,
  • Hideki Origuchi,
  • Akiko Goda,
  • Ryotaro Saita,
  • Atsushi Kikuchi

DOI
https://doi.org/10.1136/bmjopen-2023-073846
Journal volume & issue
Vol. 13, no. 8

Abstract

Read online

Introduction Cardiac rehabilitation (CR) is strongly recommended as a medical treatment to improve the prognosis and quality of life of patients with heart failure (HF); however, participation rates in CR are low compared with other evidence-based treatments. One reason for this is the geographical distance between patients’ homes and hospitals. To address this issue, we developed an integrated telerehabilitation platform, RH-01, for home-based CR. We hypothesised that using the RH-01 platform for home-based CR would demonstrate non-inferiority compared with traditional centre-based CR.Methods and analysis The E-REHAB trial aims to evaluate the efficacy and safety of RH-01 for home-based CR compared with traditional centre-based CR for patients with HF. This clinical trial will be conducted under a prospective, randomised, controlled and non-inferiority design with a primary focus on HF patients. Further, to assess the generalisability of the results in HF to other cardiovascular disease (CVD), the study will also include patients with other CVDs. The trial will enrol 108 patients with HF and 20 patients with other CVD. Eligible HF patients will be randomly assigned to either traditional centre-based CR or home-based CR in a 1:1 fashion. Patients with other CVDs will not be randomised, as safety assessment will be the primary focus. The intervention group will receive a 12-week programme conducted two or three times per week consisting of a remotely supervised home-based CR programme using RH-01, while the control group will receive a traditional centre-based CR programme. The primary endpoint of this trial is change in 6 min walk distance.Ethics and dissemination The conduct of the study has been approved by an institutional review board at each participating site, and all patients will provide written informed consent before entry. The report of the study will be disseminated via scientific fora, including peer-reviewed publications and presentations at conferences.Trial registration number jRCT:2052200064.